Since β-blockers antagonise the β-adrenergic receptors (β-ARs) in the cardiovascular system, we first evaluated the expression pattern of β-AR genes ADRB1, ADRB2 and ADRB3 in MB tumours from a cohort of 240 patients (Figures 5a-c). The gene discussed is ADRB3; the disease is neoplasm.